
Advertise on podcast: The BioCentury Show
Rating
4.6from
This podcast has
75 episodes
Language
EnglishPublisher
BioCenturyExplicit
No
Date created
2024/05/02
Latest episode
2026/10/30
Average duration
36 min.
Release period
13 days
Description
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Unlock The BioCentury Show podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from The BioCentury Show podcast
Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process
2026/10/30
On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its investment decisions. Muijrers explains how council input steered Gilde away from one deal and toward another, diagnostics company Karius, and why he argues patient perspectives belong alongside physician input in diligence and development strategy. He also describes the frameworks Gilde has developed for engaging patient organizations, and why he urges other investors to adopt them as a pre-competitive practice. This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661356
#PatientEngagement #BiotechInvesting #ImpactInvesting #VentureCapital #MarketAccess
0:00 Introduction
2:00 Creating Gilde's Impact Council
7:32 Advisors' Impact on Investing
16:42 Gilde's Approach to Patient Engagement
23:50 Where Patient Input Fits in Decision-making
29:17 Why Other Investors Should Engage
Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China
2026/10/21
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show, Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both in a single protocol can de-risk FDA acceptance while capturing China’s enrollment speed. Winterberger also discusses investigator-initiated trials in China, China’s new IIT regulations, and trial trends spanning bispecifics, ADCs, cell and gene therapies, and radiopharmaceuticals.
This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661260
#GlobalClinicalTrials #IITs #Oncology #ADCs #CRO
0:00 Introduction
1:17 Tigermed's Global Capabilities
2:59 Running Trials in China
7:05 Chinese Sponsors in the U.S.
16:42 IITs
22:28 Trends in Trial Design
Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi
2026/10/17
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once.
View full story: https://www.biocentury.com/article/661194
#RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech
0:00 Introduction
1:09 Arrowhead's siRNA Platform
9:05 Solving for Extra-Hepatic Delivery
23:43 Redemplo's Future Growth
27:00 Obesity and Bispecific siRNA
Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces
2026/10/02
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars.
View full story: https://www.biocentury.com/article/660963
#VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA
0:00 Introduction
1:19 Canaan's Strategy
11:34 Team Building
21:57 White Space
28:00 New Biotech Buyers
34:15 Biotech Founders
Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile
2026/09/18
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets.
Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway.
View full story: https://www.biocentury.com/article/660824
#Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials
0:00 Introduction
1:22 New Fund & Founding
10:30 Alnylam Deal
17:14 Working with Big Caps
25:54 Biotech Risk
29:13 China
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
2026/09/04
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics.
View full story: https://www.biocentury.com/article/660697
#Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials
0:00 - Introduction
1:14 - Regeneron Genetics Center
10:29 - Acting on Genetic Signals
16:57 - Getting to Drug Development
21:51 - Best AI Use Cases
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
2026/08/21
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients.
In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero discusses how the principal bottleneck is no longer the ability to design therapies for individual patients but rather the absence of a standardized regulatory and development system that can translate one success into many. C-Path plans to bring companies, academics, patient groups, and regulators together to share data and address recurring development bottlenecks.
View full story: https://www.biocentury.com/article/660583
#GeneticMedicines #RareDisease #DrugDevelopment #RegulatoryScience #ClinicalTrials
00:00 - Introduction
01:44 - Current Framework
07:01 - Process-based Regulation
13:57 - Overcoming Bottlenecks
20:28 - Use of AI
25:25 - Beyond Rare Diseases
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
2026/08/07
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.
View full story: https://www.biocentury.com/article/660408
#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation
00:00 - Introduction
03:24 - Biotech Under Threat
10:38 - CEO Compensation
15:39 - Competing with China
22:08 - U.S. Policy Prescriptions
30:00 - Looking Ahead
Ep. 115 - Initiate's Owens on what it takes to be AI-native
2026/07/23
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model.
Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients.
View full story: https://www.biocentury.com/article/660203
#AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment
00:00 - Introduction
01:15 - Initiate Ventures' Thesis
07:04 - What Makes Founders Fundable
17:36 - Defining AI Native Healthcare
23:20 - Diagnostics & Evidence Generation
36:44 - Non-Invasive Fibrosis Testing
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
2026/07/10
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year.
In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he views AI at Roivant and more broadly in biopharma R&D, the science behind Roivant’s next most advanced program, Phase III anti-FcRN mAb imeroprubart and the lessons he’s taking from a “graduating class” of biotechs that have launched programs, like Alnylam and Argenx S.E.
View full story: https://www.biocentury.com/article/660059
#DrugDevelopment #BiotechInnovation #Commercialization #ArtificialIntelligence #BiopharmaStrategy
00:00 - Introduction
00:42 - Roivant’s Evolution
09:19 - AI in R&D
17:48 - Lead Asset Brepocitinib
28:23 - Anti-FcRN mAb Imeroprubart
32:23 - China
37:55 - What’s Next for Roivant
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
2026/06/25
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world.
In conversation with Executive Editor Jeff Cranmer on The BioCentury Show, Jiang describes the evolution of China’s biotech ecosystem — and Hengrui's — toward first-order innovation and the changing nature of deals in China, from straightforward licensing deals with “safe money” to NewCo deals and “co-co” partnerships.
View full story: https://www.biocentury.com/article/659912
#ChinaBiotech #BiopharmaInnovation #DrugDevelopment #StrategicPartnerships #GlobalBiotech
00:00 - Introduction
01:32 - Evolution of China Biotech
08:43 - China Deals
17:23 - Hengrui’s Evolution
24:43 - Shareholder Base
26:42 - Deals
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
2026/06/18
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development.
View full story: https://www.biocentury.com/article/659807
#ArtificialIntelligence #PharmaInnovation #DrugDevelopment #DigitalTransformation #ResearchAndDevelopment
00:00 - Introduction
02:07 - Revamping Takeda for AI
19:03 - Teams & Talent
26:43 - Alliances
32:50 - Q&A
Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner
2026/06/12
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch.
On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the first validated example, and AL-S Pharma is now testing whether misfolded SOD1 marks a treatable subset of sporadic ALS. On biomarkers, she's optimistic a TDP-43 marker could arrive within two years.
View full story: https://www.biocentury.com/article/659713
#ALS #DrugDevelopment #ClinicalTrials #Biomarkers #ALSResearch
00:00 - Introduction
02:03 - ALS Mechanistic Diversity
06:13 - Trial Design Challenges
16:52 - Biomarker Toolkit Update
24:20 - ALS Pharma & SOD1
Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China
2026/05/28
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs.
As Pops prepares to retire as CEO (he will remain chairman), he spoke with BioCentury Washington Editor Steve Usdin about the ways policy and economics shape the development of medicines. Pops discussed the impact of the Trump administration’s most favored nation (MFN) drug pricing policy and the Inflation Reduction Act (IRA), concerns about FDA’s loss of talent, and competition and collaboration with China’s life sciences sector.
View full story: https://www.biocentury.com/article/659601
#DrugPricing #BiotechLeadership #FDAPolicy #LifeSciencesPolicy #DrugDevelopment
00:00 - Introduction
01:40 - Alkermes’ Evolution
05:12 - PBMs, Pricing & Access
10:54 - IRA
18:14 - MFN
24:36 - PDUFA Negotiations
28:05 - FDA Staffing
31:40 - China & U.S. Policy
Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
2026/05/15
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”
In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact.
As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing roughly $4 billion in follow-on investment across 17 companies.
View full story: https://www.biocentury.com/article/659476
#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch
00:00 - Introduction
01:34 - Optimizing Translation
07:42 - Training the Immune System
16:33 - China’s Opportunity
20:50 - Need for a Cancer Strategy
24:40 - Enhancing Cancer Survivorship
27:55 - Scientific Foundation Under Threat
Podcast reviews
Read The BioCentury Show podcast reviews
Surfrider182 2024/08/13
Wow
Insightful and full of great info every time! Thx!
Podcast sponsorship advertising
Start advertising on The BioCentury Show relevant audience podcasts
You may also like to advertise on these Podcasts

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network

4.510879779
The Joe Budden Podcast
The Joe Budden Network

4.611699506
The Bulwark Podcast
The Bulwark

4.711530393
Matt and Shane's Secret Podcast
Matt McCusker & Shane Gillis

4.72577183
Smosh Reads Reddit Stories
Smosh

4.975261756
Small Town Murder
James Pietragallo, Jimmie Whisman

4.71325596
Bulwark Takes
The Bulwark

4.8583398
Didn't I Just Feed You
Stacie Billis and Meghan Splawn

4.4503509
Warfare
History Hit

4.8296912000
Fantasy Footballers - Fantasy Football Podcast
Fantasy Football